Innovent, Lilly add deal for PD-1 bispecific antibodies

Innovent Biologics Inc. (Suzhou, China) and Eli Lilly and Co. (NYSE:LLY) signed their second deal this year, a partnership to co-develop three preclinical immuno-oncology bispecific antibodies. All three target PD-1. The second targets for each of the molecules are undisclosed, though Innovent CEO Michael Yu told BioCentury they are all "checkpoint related."

Lilly is responsible for ex-China development and commercialization, while Innovent is responsible for development and commercialization in China. Lilly has an option to co-develop the bispecific antibodies in China. ...